Jefferies On New Study From CELG

Jefferies has issued a report regarding the new study from Celgene Corp CELG. According to the report, "In advance of tomorrow's main update on the three Revlimid maintenance trials, we have learned that the French IFM study will show the first signs of a trend towards an overall survival (OS) benefit for Revlimid, a new positive data point. We have also confirmed that the statistically significant OS benefit in the U.S. CALGB study is based on a Kaplan-Meier, log-rank analysis, strengthening the robustness of this finding." CELG is Buy rated and has a $68 Price Target.